III.L 0MSFT 0.31GO.U.TO 0.3CIU.PR.A.TO 0DAL -0.02CDZ.TO 0.42NET -0.42KLAC 1.81
Stryker Corp. (SYK)

NYSE:SYK

Stryker Corp. (SYK)

326.54
-0.00 (0.00%)
as of Jul 2, 2026, 9:00:20 pm Market Open.
258 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconJul 5, 2026, 12:00 am

This summary was created by AI, based on 7 opinions in the last 12 months.

Stryker Corp (SYK) is facing a challenging environment in the medtech sector, characterized by weakness due to a post-Covid normalization and ongoing issues, including a cybersecurity attack that affected production. Despite these hurdles, experts largely recognize Stryker's strong market position, particularly in orthopedics, which continues to be a profitable segment for U.S. hospitals. The company has a robust relationship with medical professionals and is expected to grow its revenue at high single-digit rates. Analysts predict significant earnings growth, with a projected EPS of $15 by 2027, supported by an attractive valuation. As the population ages, the demand for artificial joints and robotic-assisted surgeries is expected to rise, positioning Stryker favorably in the long term.

consensus icon
Consensus
Hold
valuation icon
Valuation
Undervalued
review icon
Similar
Pfeizer, PFE
PARTIAL BUY

Stryker Corp.(SYK)

Aug 25, 2020

They're the leader in hips, knees and robotic surgeries. They were hit by COVID because elective surgeries stopped, but those have resumed now. Their revenue growth is 4-5 times higher than peers at 6-7% while peers like Johnson and Johnson were 1-2%. Dividends keep paying. Today is okay to enter this stock, though it's trading at 30x earnings. You can buy a half position now and see what happens.

Photo of David DriscollDavid Driscoll
Owned
Unlock Rating
$188.51

Stock price when the opinion was issued

$326.54

As of Jul 02, 2026. Market Open.

biotechnologypharmaceutical
BUY

Stryker Corp.(SYK)

Aug 25, 2020
Allan Tong’s Discover Picks Stryker enjoyed a bounce after beating Q2 revenues and earnings a month ago, but has been rangebound between $180 and $205 since Easter. Typical of the other medical device stocks here, it has yet to return to pre-COVID highs of $226, but trades at a 27.44x PE, far more reasonable than peers including Intuitive Surgical. Read BDX, BSX, ISRG and Stryker Stock: Top 4 Medical Supply Stocks for our full analysis.
Photo of Stockchase DiscoverStockchase Discover
Owned
Unlock Rating
$189.57

Stock price when the opinion was issued

$326.54

As of Jul 02, 2026. Market Open.

biotechnologypharmaceutical
BUY

Stryker Corp.(SYK)

Aug 20, 2020
Medical devices have had a tough year, as elective surgeries have been put on hold. Will continue to do well as surgeries come back. Steep learning curve when it comes to these products, so that's a risk. But once doctors learn the mechanics, they're repeat users. Demographic play. At a good level here.
Photo of Paul Harris, CFAPaul Harris, CFAUnlock Rating
$188.53

Stock price when the opinion was issued

$326.54

As of Jul 02, 2026. Market Open.

biotechnologypharmaceutical
BUY

Stryker Corp.(SYK)

Aug 11, 2020

Medtronic vs. Stryker Both make medical devices, and have been impacted by COVID, because operations have been delayed. But now those ops are coming back. She owns JNJ instead, which includes a medical devices division. Unless there's a sharp uptick in the virus that shuts down hospitals again, demand for medical devices should rise and should even ramp in the near future.

Photo of Christine PooleChristine Poole
No
Unlock Rating
$191.41

Stock price when the opinion was issued

$326.54

As of Jul 02, 2026. Market Open.

biotechnologypharmaceutical
BUY

Stryker Corp.(SYK)

Jul 31, 2020
He just bought a huge chunk this morning. A company that makes medical devices and is the leader in hips, knees and shoulder replacement. The sales force is their moat. It is able to pivot really quickly. They produce the best products, makes good acquisitions and deploys cash well.
Photo of Barry SchwartzBarry Schwartz
Owned
Unlock Rating
$193.30

Stock price when the opinion was issued

$326.54

As of Jul 02, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Stryker Corp.(SYK)

Jul 21, 2020
They make medical and surgical equipment in orthopedics. They just bought a hands-and-ankles medical company. Most elective surgeries were postponed in the pandemic, but are slowly coming back now which benefits SYK. Salespeople are very knowledgeable about their products. Doctors remain loyal to SYK's products and won't switch to another company. (Analysts’ price target is $205.79)
Photo of Paul Harris, CFAPaul Harris, CFA
Owned
Unlock Rating
$192.71

Stock price when the opinion was issued

$326.54

As of Jul 02, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Stryker Corp.(SYK)

Jun 26, 2020
A medical device company. Elective surgeries have been slowed during the pandemic, but will still need to done. Demographics mean this will continue to grow. There is brand loyalty in the space as parts are not easily exchangeable. About 25% of cash flow goes to dividends and the rest towards acquisitions and paying down debt. Yield 1.31% (Analysts’ price target is $205.63)
Photo of Paul Harris, CFAPaul Harris, CFA
Owned
Unlock Rating
$175.86

Stock price when the opinion was issued

$326.54

As of Jul 02, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Stryker Corp.(SYK)

May 11, 2020
(A Top Pick May 21/19, Up 4%) It is a good opportunity to buy the stock right here. Elective surgeries are shut down and have to come back. You may have tougher quarters over the next little while.
Photo of Paul Harris, CFAPaul Harris, CFA
Owned
Unlock Rating
$193.64

Stock price when the opinion was issued

$326.54

As of Jul 02, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Stryker Corp.(SYK)

Apr 23, 2020
The analysts are calling for about $8 a share which gives a PE of 20 at current prices. The fair market value is a little below the current stock price. His target is about $210 and is an upper boundary. The bottom would be $132. (Analysts’ price target is $8.00)
Photo of Ross HealyRoss HealyUnlock Rating
$185.02

Stock price when the opinion was issued

$326.54

As of Jul 02, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Stryker Corp.(SYK)

Apr 16, 2020
(A Top Pick Jun 04/19, Down 7%) He really likes the equipment side of the healthcare industry. There is a bit of a lag for the kind of procedures they are doing. The demographic is really good and people will continue to need knees and hips and so on. He is looking to add more to this industry. He continues to hold it.
Photo of Zachary Curry Zachary Curry
Owned
Unlock Rating
$174.87

Stock price when the opinion was issued

$326.54

As of Jul 02, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Stryker Corp.(SYK)

Apr 07, 2020

Likes it. He hasn't bought it, because he isn't sure which stock to own in this sector. Abbott and Boston Scientific are better choices, he thinks, with more upside potential given product innovation.

Photo of David FingoldDavid Fingold
No
Unlock Rating
$171.58

Stock price when the opinion was issued

$326.54

As of Jul 02, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Stryker Corp.(SYK)

Mar 12, 2020
(A Top Pick May 21/19, Down 16%) Medical devices, which is very strong. It's a practical way to keep people out of hospitals. Great story about demographics.
Photo of Paul Harris, CFAPaul Harris, CFA
Owned
Unlock Rating
$154.25

Stock price when the opinion was issued

$326.54

As of Jul 02, 2026. Market Open.

biotechnologypharmaceutical
BUY ON WEAKNESS

Stryker Corp.(SYK)

Feb 26, 2020

A great medical equipment company. Over time, they've consolidated and grown. Demographic trends are on his side. But he owns Abbott instead; you can't own everything. Wait for more of a pullback to buy. If the PE falls to the low-$20s, step in.

Photo of Chris BlumasChris Blumas
No
Unlock Rating
$201.66

Stock price when the opinion was issued

$326.54

As of Jul 02, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Stryker Corp.(SYK)

Feb 21, 2020

A manufacturer of medical and surgical devices. The company has had positive sales growth for over 40 years. They do a great job at identifying areas where they are weak, finding a way to fill that gap and executing the strategy quickly. There is not much exposure they hold in China -- fortuitous right now. Yield 1.03% (Analysts’ price target is $232.92)

Photo of Ian FungIan Fung
Owned
Unlock Rating
$223.46

Stock price when the opinion was issued

$326.54

As of Jul 02, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Stryker Corp.(SYK)

Feb 18, 2020
A good acquirer and integrator and have a good position in hip and knee replacement. They're aiming for 1,000 robotic installations worldwide, now at 850. They took a drop in their last purchase but they've bounced back. (Analysts’ price target is $232.92)
Photo of Michael DecterMichael Decter
Owned
Unlock Rating
$221.93

Stock price when the opinion was issued

$326.54

As of Jul 02, 2026. Market Open.

biotechnologypharmaceutical
Showing 76 to 90 of 171 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

NFLX 0$77.65
GOOG -0.5$355.68
CAT 1.47$965
NFLX 0$77.65
AAPL -0.2$308.43
The ultimate 360° Tracker Your financial life in one place, automaticallywealthica-video

Today's Top Picks

III.L 0$2999
MSFT 0.31$390.8
GO.U.TO 0.3$9.55
CIU.PR.A… 0$
DAL -0.02$92.73

Popular Articles

Latest Sell Signals

CAT 1.47$965
ASML 5.87$1775.1899
TRI.TO -1.74$124.88
EIF.TO 2.09$132.94
MU 0.84$976.4

Most Recent Experts

Malcolm Ethridge, Mgn. partner, Capital Area Planning Group

Malcolm Ethridge, Mgn. partner, Capital Area Planning Group

Capital Area Planning Group

Kevin Simpson

Kevin Simpson

Capital Wealth Planning

Josh Brown, CEO, Ritholtz Wealth Management

Josh Brown, CEO, Ritholtz Wealth Management

Ritholtz Wealth Management

Michael Hakes - CFA, MBA

Michael Hakes - CFA, MBA

Murray Wealth Group

Stephanie Link, Chief investment strategist, Hightower

Stephanie Link, Chief investment strategist, Hightower

Hightower

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica

You may also like